Design Therapeutics (DSGN) EBT (2020 - 2026)
Design Therapeutics' (DSGN) quarterly EBT came in at -$17.6 million in Q1 2026, little changed year-on-year from -$17.6 million in Q1 2025, and down 10.25% quarter-over-quarter from -$16.0 million in Q4 2025.
Design Therapeutics (DSGN) EBT (2020 - 2026) Analysis & Trends
Design Therapeutics has disclosed EBT across 7 years of filings, most recently posting -$17.6 million for Q1 2026.
- EBT for Q1 2026 came in at -$17.6 million, changed 0.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$69.7 million (down 24.05% YoY), and the FY2025 annual result was -$69.8 million, down 40.74% from the prior year.
- EBT came in at -$17.6 million for Q1 2026 at Design Therapeutics, down from -$16.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$11.1 million in Q1 2024 to a low of -$22.6 million in Q2 2023.
- The 5-year median for EBT is -$17.0 million (2025), against an average of -$16.6 million.
- Across the five-year window, EBT sank 135.39% in 2022 and jumped 48.71% in 2024, its largest moves.
- Design Therapeutics' EBT stood at -$19.4 million in 2022, then climbed by 22.02% to -$15.1 million in 2023, then grew by 9.72% to -$13.7 million in 2024, then declined by 17.19% to -$16.0 million in 2025, then declined by 10.25% to -$17.6 million in 2026.
- The last three EBT figures came in at -$17.6 million (Q1 2026), -$16.0 million (Q4 2025), and -$17.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Design Therapeutics | 763.94 Mn | 541.11 Mn | - | -17.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.64 Mn |
| Dec 31, 2025 | -16.00 Mn |
| Sep 30, 2025 | -17.00 Mn |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -17.72 Mn |
| Dec 31, 2024 | -13.65 Mn |
| Sep 30, 2024 | -13.04 Mn |
| Jun 30, 2024 | -11.79 Mn |
| Mar 31, 2024 | -11.11 Mn |
| Dec 31, 2023 | -15.12 Mn |
| Sep 30, 2023 | -18.82 Mn |
| Jun 30, 2023 | -22.60 Mn |
| Mar 31, 2023 | -21.65 Mn |
| Dec 31, 2022 | -19.39 Mn |
| Sep 30, 2022 | -19.19 Mn |
| Jun 30, 2022 | -15.64 Mn |
| Mar 31, 2022 | -13.37 Mn |
| Dec 31, 2021 | -11.13 Mn |
| Sep 30, 2021 | -11.34 Mn |
| Jun 30, 2021 | -7.69 Mn |